요약정보
Minimizing DILI risk in drug discovery - A screening tool for drug candidates.
- Resource Type
- Academic Journal
- Authors
- Schadt S; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland. Electronic address: simone.schadt@roche.com.; Simon S; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland. Electronic address: silke.simon@roche.com.; Kustermann S; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland. Electronic address: stefan.kustermann@roche.com.; Boess F; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland. Electronic address: franziska.boess@roche.com.; McGinnis C; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland. Electronic address: claudia.mcginnis@roche.com.; Brink A; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland. Electronic address: andreas.brink@roche.com.; Lieven R; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland. Electronic address: rebecca.lieven@roche.com.; Fowler S; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland. Electronic address: stephen.fowler@roche.com.; Youdim K; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland. Electronic address: kuresh.youdim@roche.com.; Ullah M; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland. Electronic address: mohammed.ullah@roche.com.; Marschmann M; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland. Electronic address: michaela.marschmann@roche.com.; Zihlmann C; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland. Electronic address: christine.zihlmann@roche.com.; Siegrist YM; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland. Electronic address: yves_martin.siegrist@roche.com.; Cascais AC; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland. Electronic address: anne-christine.cascais@roche.com.; Di Lenarda E; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland. Electronic address: elisa.di_lenarda@roche.com.; Durr E; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland. Electronic address: evelyne.durr@roche.com.; Schaub N; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland. Electronic address: nathalie.schaub@roche.com.; Ang X; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland.; Starke V; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland. Electronic address: volkmar.starke@roche.com.; Singer T; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland. Electronic address: thomas.singer@roche.com.; Alvarez-Sanchez R; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland. Electronic address: ruben.alvarez_sanchez@roche.com.; Roth AB; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland. Electronic address: adrian_b.roth@roche.com.; Schuler F; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland. Electronic address: franz.schuler@roche.com.; Funk C; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Str. 124, 4070 Basel, Switzerland. Electronic address: christoph.funk@roche.com.
- Source
- Publisher:
Pergamon Press Country of Publication: England NLM ID: 8712158 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-3177 (Electronic) Linking ISSN:08872333 NLM ISO Abbreviation: Toxicol In Vitro Subsets: MEDLINE - Subject
- Language
- English